Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels
09:10am, Tuesday, 23'rd Jan 2024
The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.
Novartis CEO explains discusses how AI will impact drug development
10:50am, Wednesday, 17'th Jan 2024
One of the top topics at the World Economic Forum is generative AI, with endless discussions on how it can impact a broad range of sectors and businesses. Pharmaceutical drug development is one of tho
These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High
02:18pm, Tuesday, 16'th Jan 2024
As investors, our job isn't to predict an unknowable future.
Novartis (NVS) Stock Drops Despite Market Gains: Important Facts to Note
07:34pm, Friday, 12'th Jan 2024
The latest trading day saw Novartis (NVS) settling at $107.45, representing a -0.14% change from its previous close.
Cytokinetics stock plunges as Novartis retreats from merger talks
05:37pm, Thursday, 11'th Jan 2024
Cytokinetics stock plunged more than 16% Thursday to $84.95 after talks reportedly broke down with potential potential buyer Novartis AG (ADR) (NYSE:NVS). Shares of the biopharmaceutical company hav
Novartis Pursuit of Cytokinetics Cools
12:19pm, Thursday, 11'th Jan 2024
Novartis has backed away from its pursuit of Cytokinetics.
Bullish Continuation in '24? 3 Market Areas to Watch
02:17pm, Wednesday, 10'th Jan 2024
Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
08:01am, Wednesday, 10'th Jan 2024
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
Novartis AG (NVS) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)
02:50pm, Tuesday, 09'th Jan 2024
Novartis AG (NVS) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)
Novartis CEO Vasant Narasimhan: The right story for the company was to focus on R&D
12:22pm, Tuesday, 09'th Jan 2024
Novartis CEO Vasant Narasimhan joins 'Money Movers' to discuss the company's overall M&A strategy, the businesses that Narasimhan wanted to get out of, and how big the Entresto drug can be.
Novartis in advanced talks to buy Cytokinetics
03:29pm, Monday, 08'th Jan 2024
Cytokinetics Inc (NASDAQ: CYTK) popped another 15% on Monday following a report that Novartis AG (SWX: NOVN) is now in advanced talks to acquire the biopharmaceutical firm.
Novartis, Cytokinetics near merger: report
01:25pm, Monday, 08'th Jan 2024
Novartis NOVN, +0.43% is close to acquiring Cytokinetics Inc. CYTK, +15.04% and its promising heart drug, according to a Wall Street Journal report Monday. A deal for South San Francisco-based Cytokin
Novartis in Advanced Talks to Buy Cytokinetics
12:56pm, Monday, 08'th Jan 2024
Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug.
Voyager Therapeutics stock pops 30% on deal with Novartis
09:25am, Monday, 08'th Jan 2024
Voyager Therapeutics Inc. NASDAQ: VYGR is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took a 30% spike on news of its partnership with Novart
2 low-priced gene therapy stocks to speculate on
08:26am, Monday, 08'th Jan 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic differences.
